ArticlePharmacoEconomics2005
Willingness to pay for inhaled insulin: a contingent valuation approach.
Article in PharmacoEconomics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The patient perspective of diabetes care: a systematic review of stated preference research.The patient · 2014Pooled it
- Psychological insulin resistance: patient beliefs and implications for diabetes management.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2009Pooled it
- Physicians' preferences and willingness to pay for artificial intelligence-based assistance tools: a discrete choice experiment among german radiologists.BMC health services research · 2022Article
- Emotions and scope effects in the monetary valuation of health.The European journal of health economics : HEPAC : health economics in prevention and care · 2018Article
- Preference for pharmaceutical formulation and treatment process attributes.Patient preference and adherence · 2016Review
- Patient preferences for the treatment of type 2 diabetes: a scoping review.PharmacoEconomics · 2013Article
- A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management.Patient preference and adherence · 2010Article
- Willingness-to-pay to avoid the time spent and discomfort associated with screening colonoscopy.Health economics · 2010Article
- Exploring patients' perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study.Patient preference and adherence · 2010Article
- Patients' Preferences for Generic and Branded Over-the-Counter Medicines: An Adaptive Conjoint Analysis Approach.The patient · 2009Article
- Willingness to pay to sustain and expand National Health Insurance services in Taiwan.BMC health services research · 2008Article
- A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?PharmacoEconomics · 2007Review
- Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus.Drugs · 2006 · on this mapReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the willingness to pay (WTP) of patients with diabetes mellitus for inhaled insulin.
methodsA contingent valuation survey was administered to 96 diabetic outpatients at St. Michael's Hospital, Toronto, Canada. Standardised information about inhaled insulin and subcutaneous rapid-acting insulin was provided via video. Participants' WTP for their preferred product was elicited in Canadian dollars (Can dollars) using a 'payment-scale' method.
resultsThe mean age of participants was 51.8 years (SD 13.4). Seventy-seven patients had type 2 and 19 had type 1 diabetes. Significantly more participants preferred inhaled insulin over subcutaneous insulin (85 vs 11; p < 0.01). Mean monthly WTP for inhaled insulin (153.70 Can dollars, SD 99.90) was significantly more than the typical 50 Can dollars per month for subcutaneous insulin (p < 0.01). Significantly more participants with type 2 diabetes using oral drugs than those with type 1 diabetes and using insulin preferred inhaled insulin (98.5% vs 69%, p < 0.001). Diabetic patients who did not use insulin were willing to pay significantly more than were insulin users (p < 0.001). Multiple regression analysis showed that income was significantly associated with WTP for inhaled insulin.
conclusionDiabetic patients, particularly those who are not using insulin, indicated that they would prefer inhaled insulin over insulin injection and would be willing to pay a substantial amount per month to use it. An economic evaluation of inhaled insulin would provide important information to healthcare policy decision makers and private payers about its economic value.
Indexed as
Identifiers
16336016What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.